| Journal: | Memorias do Instituto Oswaldo Cruz |
| Database: | PERIÓDICA |
| System number: | 000437055 |
| ISSN: | 0074-0276 |
| Authors: | Biembengut, Isis Venturi1 Souza, Tatiana de Arruda Campos Brasil de1 |
| Institutions: | 1Fundacao Oswaldo Cruz, Instituto Carlos Chagas, Curitiba, Parana. Brasil |
| Year: | 2020 |
| Volumen: | 115 |
| Country: | Brasil |
| Language: | Inglés |
| Document type: | Nota breve o noticia |
| Approach: | Experimental, aplicado |
| English abstract | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection depends on viral polyprotein processing, catalysed by the main proteinase (Mpro). The solution of the SARS-CoV-2 Mpro structure allowed the investigation of potential inhibitors. This work aims to provide first evidences of the applicability of commercially approved drugs to treat coronavirus disease-19 (COVID-19). We screened 4,334 compounds to found potential inhibitors of SARS-CoV-2 replication using an in silico approach. Our results evidenced the potential use of coagulation modifiers in COVID-19 treatment due to the structural similarity of SARS-CoV-2 Mpro and human coagulation factors thrombin and Factor Xa. Further in vitro and in vivo analysis are needed to corroborate these results |
| Disciplines: | Medicina |
| Keyword: | Química farmacéutica, COVID-19, SARS-CoV-2, Proteasas, Coagulación |
| Keyword: | Medicinal chemistry, Proteases, Coagulation, COVID-19, SARS-CoV-2 |
| Full text: | Texto completo (Ver HTML) Texto completo (Ver PDF) |
